북미 비소세포 폐암 진단 시장 – 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력: 북미 비소세포 폐암 진단 시장

북미 비소세포 폐암 진단 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년부터 2028년까지의 예측 기간 동안 13.0%의 CAGR로 성장하고 있으며 2028년까지 1,440.42백만 달러에 도달할 것으로 예상된다고 분석합니다.

비소세포성 폐암은 악성 세포 또는 암세포가 폐 조직에 형성되는 질병입니다. 이들은 여러 유형이며 각 유형은 서로 다른 방식으로 자라고 퍼집니다. 비소세포성 폐암(NSCLC) 유형은 편평세포암, 대세포암 및 선암입니다. 편평세포암의 경우 암은 폐 내부를 덮고 있는 얇고 평평한 세포에서 형성되며 표피모양 암이라고도 합니다. 대세포암 암은 여러 유형의 대세포에서 시작되고 선암 유형의 암은 폐포를 덮고 점액과 같은 물질을 만드는 세포에서 시작됩니다. 비소세포성 폐암(NSCLC)의 주요 위험 중 하나는 흡연이며 증상에는 사라지지 않는 기침과 호흡 곤란이 포함됩니다. 영상 검사, 분자 검사, 생검 등과 같은 다양한 검사를 사용하여 암 단계를 진단하고 검사합니다. 진단은 적절한 치료를 제공할 수 있도록 제때 질병을 식별하는 데 중요합니다.

비소세포 폐암 진단 시장 성장을 견인하는 요인은 비소세포 폐암에 더 취약한 고령 인구의 증가와, 국내 및 글로벌 기업 간의 치열한 시장 경쟁이 비소세포 폐암 진단 시장 성장을 제한할 수 있다는 점입니다.

비소세포 폐암 진단 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 머신 비전 물류 시장 시나리오를 이해하려면 Data Bridge Market Research에 연락하여 분석가 브리핑을 요청하세요. 당사 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드립니다.

북미 비소세포 폐암 진단 시장 범위 및 시장 규모

The North America non-small cell lung cancer diagnostics market is segmented into four notable segments based on the lung cancer type, product, test and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of cancer type, the North America non-small cell lung cancer diagnostics market is segmented into lung adenocarcinoma (LUAD), lung squamous cellcarcinoma (LUSC), large cell carcinoma and others. In 2021, the lung adenocarcinoma (LUAD) segment is expected to dominate the non-small cell lung cancer diagnostics market due to the high prevalence of the Lung Adenocarcinoma among all type of non-small cell lung cancer.
• On the basis of product, the North America non-small cell lung cancer diagnostics market is segmented into reagents & kits, instruments and services & softwares. In 2021, the instrument segment is expected to dominate the non-small cell lung cancer diagnostics market due to the availability of the instrument along with advancement in the technology.
• On the basis of test, the North America non-small cell lung cancer diagnostics market is segmented imaging test, molecular test, biopsy, sputum cytology, thoracentesis, immunohistochemistry and others. In 2021, the molecular test segment is expected to dominate the non-small cell lung cancer diagnostics market due to rising need of molecular tests to diagnose non-small cell lung cancer accurately and efficiently.
• On the basis of end user, the North America non-small cell lung cancer diagnostics market is segmented into hospital, clinical laboratories, academics and others. In 2021, the clinical laboratories segment is expected to dominate the non-small cell lung cancer diagnostics market due to the growing clinical research in cancer.

North America Non-Small Cell Lung Cancer Diagnostics Market: Country Level Analysis

North America non-small cell lung cancer diagnostics market is analyzed and market size information is provided by country, lung cancer type, products, test and end user.

Countries covered in the North America Non-small cell lung cancer diagnostics market report are US, Canada and Mexico.

US is dominating the non-small cell lung cancer diagnostics market with the highest CAGR and highest market share due to growing cases of cancer in U.S.

In U.S., Lung Adenocarcinoma (LUAD) segment is growing due to high prevalence of lung adenocarcinoma among types of non-small cell lung cancer. In Canada, the Lung Adenocarcinoma (LUAD) segment is growing due to rise in need for molecular tests to diagnose non-small cell lung cancer accurately. In Mexico, the Lung Adenocarcinoma (LUAD) segment is growing due to advancements made in technology used in the clinical laboratory to detect molecular abnormalities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rising Demand of Diagnostic in Medical Setting

North America non-small cell lung cancer diagnostics market also provides you with detailed market analysis for every country growth in industry with sales, components sales, impact of technological development in non-small cell lung cancer diagnostics, and changes in regulatory scenarios with their support for the non-small cell lung cancer diagnostics market. The data is available for historic period 2010 to 2019.

Competitive Landscape and North America Non-Small Cell Lung Cancer Diagnostics Market Share Analysis

North America non-small cell lung cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, India presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve. The above data points provided are only related to the companies’ focus related to non-small cell lung cancer diagnostics market.

Some of the major players operating in the non-small cell lung cancer diagnostics market are Abbott, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString, Janssen Pharmaceutical NV, Inivata Ltd, bioMérieux SA, Biotheranostics, OncoCyte Corporation Inc., GENERAL ELECTRIC COMPANY, Eckert & Ziegler, DrLal PathLabs, RIVERAIN TECHNOLOGIES, PlexBio Co.,Ltd, Oncimmune, and Biodesix among others.

North America non-small cell lung cancer diagnostics market is fragmented and the major players have used various strategies such as collaborations, recognitions, agreements, and others, to increase their footprints in the non-small cell lung cancer diagnostics market.

For instance,

• In March 2021, Agilent Technologies, Inc. acquired Resolution Bioscience for USD 550 million to strengthen its business in next-generation sequencing (NGS)-based oncology solutions
• In May 2021, QIAGEN launched FDA approved therascreen KRAS RGQ PCR Kit, which aids in the identification of non-small cell lung cancer (NSCLC) in patients
• 2020년 6월, F. Hoffmann-La Roche Ltd는 비소세포폐암(NSCLC)을 진단하고 진단 치료의 속도와 정확도를 개선하기 위해 자동화된 디지털병리학 알고리즘인 uPath PD-L1(SP263) 이미지 분석을 출시했습니다.

SKU-64358